- Home
- SOLV vs ITCI Comparison
SOLV vs ITCI Comparison
Compare SOLV & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- ITCI
- Stock Information
- Founded
- SOLV 2023
- ITCI 2002
- Country
- SOLV United States
- ITCI United States
- Employees
- SOLV N/A
- ITCI N/A
- Industry
- SOLV
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- SOLV
- ITCI Health Care
- Exchange
- SOLV NYSE
- ITCI Nasdaq
- Market Cap
- SOLV 11.1B
- ITCI 8.0B
- IPO Year
- SOLV N/A
- ITCI N/A
- Fundamental
- Price
- SOLV $72.18
- ITCI $74.70
- Analyst Decision
- SOLV Hold
- ITCI Strong Buy
- Analyst Count
- SOLV 6
- ITCI 11
- Target Price
- SOLV $58.25
- ITCI $97.00
- AVG Volume (30 Days)
- SOLV 1.1M
- ITCI 456.3K
- Earning Date
- SOLV 11-03-2024
- ITCI 10-31-2024
- Dividend Yield
- SOLV N/A
- ITCI N/A
- EPS Growth
- SOLV N/A
- ITCI N/A
- EPS
- SOLV 6.12
- ITCI N/A
- Revenue
- SOLV $8,207,000,000.00
- ITCI $564,526,000.00
- Revenue This Year
- SOLV $2.07
- ITCI $46.60
- Revenue Next Year
- SOLV $0.14
- ITCI $37.06
- P/E Ratio
- SOLV $11.80
- ITCI N/A
- Revenue Growth
- SOLV 1.31
- ITCI 54.31
- 52 Week Low
- SOLV $47.16
- ITCI $45.50
- 52 Week High
- SOLV $73.40
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- ITCI 50.77
- Support Level
- SOLV N/A
- ITCI $73.05
- Resistance Level
- SOLV N/A
- ITCI $76.98
- Average True Range (ATR)
- SOLV 0.00
- ITCI 1.81
- MACD
- SOLV 0.00
- ITCI 0.23
- Stochastic Oscillator
- SOLV 0.00
- ITCI 56.41
About SOLV SOLVENTUM CORP
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.